KeyBank National Association
ABEO icon

KeyBank National Association’s Abeona Therapeutics ABEO Stock Holding History

KeyBank National Association’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-742
Closed -$89K – 982
2019
Q2 		$89K Buy
+742
New +$124K ﹤0.01% 986
2018
Q2 		– Sell
-548
Closed -$197K – 1040
2018
Q1 		$197K Buy
+548
New +$204K ﹤0.01% 992

Other funds holding ABEO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KeyBank National Association's ABEO Position: Q3 2019 in Review

KeyBank National Association sold out of Abeona Therapeutics (ABEO) in Q3 2019, closing a stake of 742 shares — an estimated $89K sold.

KeyBank National Association first reported a position in ABEO in Q1 2018 and held it in 2 quarters. The position peaked at $197K in Q1 2018. 79 funds tracked by Wall St. Rank hold ABEO as of Q3 2019.

  • KeyBank National Association reported no remaining Abeona Therapeutics position as of Q3 2019 after selling out during the quarter.
  • KeyBank National Association sold 742 Abeona Therapeutics shares in Q3 2019, an estimated $89K.
  • KeyBank National Association first reported a position in Abeona Therapeutics in Q1 2018 and held it in 2 quarters.
  • KeyBank National Association's Abeona Therapeutics position peaked at $197K in Q1 2018.
  • 79 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2019.

Based on KeyBank National Association's 13F filing for Q3 2019, filed 4 Nov 2019.